Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: 360iResearch | PRODUCT CODE: 1602811

Cover Image

PUBLISHER: 360iResearch | PRODUCT CODE: 1602811

Antibacterial Drugs Market by Routes of Administration (Enteral, Parenteral), Drug Class (Aminoglycoside, B - Lactams, Macrolides), Distribution Channel - Global Forecast 2025-2030

PUBLISHED:
PAGES: 186 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF, Excel & 1 Year Online Access (Single User License)
USD 3939
PDF, Excel & 1 Year Online Access (Enterprise User License)
USD 6969

Add to Cart

The Antibacterial Drugs Market was valued at USD 37.63 billion in 2023, expected to reach USD 39.15 billion in 2024, and is projected to grow at a CAGR of 4.12%, to USD 49.94 billion by 2030.

The market for antibacterial drugs encompasses a wide array of therapeutic agents designed to combat bacterial infections. These drugs play a critical role in both healthcare and agricultural sectors, countering diseases that range from mild to life-threatening. The necessity of antibacterial drugs is underscored by the persistent threat of bacterial infections, heightened by the rise of antibiotic-resistant strains, which significantly underscores their application in treating conditions such as pneumonia, tuberculosis, and urinary tract infections, among others. End-use sectors predominantly include hospitals, clinics, and outpatient facilities, while the veterinary industry and agriculture also represent significant application areas. A key influencer of market growth is the increasing prevalence of infectious diseases, coupled with heightened awareness and diagnostic advancements. Moreover, the constant evolution of bacterial resistance patterns stimulates ongoing innovation and R&D efforts into new drug classes, thus opening potential opportunities for companies to invest in the development of novel antibacterial agents or formulations with better efficacy and safety profiles. However, the market faces substantial limitations, notably the high costs and lengthy timelines associated with research and development, regulatory hurdles, and the potential for adverse effects, which restrict the proliferation of new drugs. Furthermore, the widespread misuse or overuse of existing antibiotics exacerbates resistance issues, posing a challenge to industry growth. To overcome these limitations, the sector is poised for innovation, especially in developing narrow-spectrum antibiotics, alternative therapies such as phage therapy and probiotics, and rapid diagnostics that guide precise antimicrobial use. Businesses should also focus on collaborations and partnerships to expedite product development timelines and enhance market penetration. The market's dynamic nature requires continuous adaptation to technological and regulatory changes, emphasizing the importance for companies to stay abreast of advancements and evolving bacterial resistance trends to secure sustained growth and contribute to global health improvements.

KEY MARKET STATISTICS
Base Year [2023] USD 37.63 billion
Estimated Year [2024] USD 39.15 billion
Forecast Year [2030] USD 49.94 billion
CAGR (%) 4.12%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Antibacterial Drugs Market

The Antibacterial Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing prevalence of infectious diseases
    • Increasing approval and launch of new antibacterial drugs
    • Widespread of the generic drugs
  • Market Restraints
    • Patent expiry of the antibacterial drug
  • Market Opportunities
    • Innovation in some novel compounds with improved efficacy, and fewer side effects associated with the drugs
    • Adoption of antibacterial drugs in emerging countries
  • Market Challenges
    • Presence of multi-drug resistant bacterial strains

Porter's Five Forces: A Strategic Tool for Navigating the Antibacterial Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Antibacterial Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Antibacterial Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Antibacterial Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Antibacterial Drugs Market

A detailed market share analysis in the Antibacterial Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Antibacterial Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Antibacterial Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Antibacterial Drugs Market

A strategic analysis of the Antibacterial Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Antibacterial Drugs Market, highlighting leading vendors and their innovative profiles. These include Allecra Therapeutics GmbH, Allergan PLC, AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Company, Debiopharm Group, Eli Lilly and Company, Entasis Therapeutics by Innoviva, Inc., GlaxoSmithKline PLC, Iterum Therapeutics PLC, Johnson & Johnson Services Inc., Kyorin Pharmaceutical Co., Ltd., Melinta Therapeutics LLC, Merck & Co., Inc., Sanofi-Aventis Groupe S.A., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Antibacterial Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Routes of Administration, market is studied across Enteral and Parenteral.
  • Based on Drug Class, market is studied across Aminoglycoside, B - Lactams, Macrolides, Phenicols, Quinolones, Sulfonamide, and Tetracycline.
  • Based on Distribution Channel, market is studied across Drug Stores & Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Product Code: MRR-4358BACA8012

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of infectious diseases
      • 5.1.1.2. Increasing approval and launch of new antibacterial drugs
      • 5.1.1.3. Widespread of the generic drugs
    • 5.1.2. Restraints
      • 5.1.2.1. Patent expiry of the antibacterial drug
    • 5.1.3. Opportunities
      • 5.1.3.1. Innovation in some novel compounds with improved efficacy, and fewer side effects associated with the drugs
      • 5.1.3.2. Adoption of antibacterial drugs in emerging countries
    • 5.1.4. Challenges
      • 5.1.4.1. Presence of multi-drug resistant bacterial strains
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Antibacterial Drugs Market, by Routes of Administration

  • 6.1. Introduction
  • 6.2. Enteral
  • 6.3. Parenteral

7. Antibacterial Drugs Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Aminoglycoside
  • 7.3. B - Lactams
  • 7.4. Macrolides
  • 7.5. Phenicols
  • 7.6. Quinolones
  • 7.7. Sulfonamide
  • 7.8. Tetracycline

8. Antibacterial Drugs Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Drug Stores & Retail Pharmacies
  • 8.3. Hospital Pharmacies
  • 8.4. Online Pharmacies

9. Americas Antibacterial Drugs Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Antibacterial Drugs Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Antibacterial Drugs Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Allecra Therapeutics GmbH
  • 2. Allergan PLC
  • 3. AstraZeneca PLC
  • 4. Bayer AG
  • 5. Bristol-Myers Squibb Company
  • 6. Debiopharm Group
  • 7. Eli Lilly and Company
  • 8. Entasis Therapeutics by Innoviva, Inc.
  • 9. GlaxoSmithKline PLC
  • 10. Iterum Therapeutics PLC
  • 11. Johnson & Johnson Services Inc.
  • 12. Kyorin Pharmaceutical Co., Ltd.
  • 13. Melinta Therapeutics LLC
  • 14. Merck & Co., Inc.
  • 15. Sanofi-Aventis Groupe S.A.
  • 16. Teva Pharmaceutical Industries Ltd.
Product Code: MRR-4358BACA8012

LIST OF FIGURES

  • FIGURE 1. ANTIBACTERIAL DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. ANTIBACTERIAL DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ANTIBACTERIAL DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. ANTIBACTERIAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANTIBACTERIAL DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTIBACTERIAL DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY ENTERAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY AMINOGLYCOSIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY B - LACTAMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY MACROLIDES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY PHENICOLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY QUINOLONES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY SULFONAMIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY TETRACYCLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG STORES & RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANTIBACTERIAL DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES ANTIBACTERIAL DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 48. AUSTRALIA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 51. CHINA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 54. INDIA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 57. INDONESIA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 60. JAPAN ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 63. MALAYSIA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 66. PHILIPPINES ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 69. SINGAPORE ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 72. SOUTH KOREA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 75. TAIWAN ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 78. THAILAND ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 81. VIETNAM ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 88. DENMARK ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 91. EGYPT ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 94. FINLAND ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 97. FRANCE ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 100. GERMANY ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 103. ISRAEL ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 106. ITALY ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 109. NETHERLANDS ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 112. NIGERIA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 115. NORWAY ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 118. POLAND ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 121. QATAR ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 124. RUSSIA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 127. SAUDI ARABIA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH AFRICA ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 133. SPAIN ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 136. SWEDEN ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 139. SWITZERLAND ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 142. TURKEY ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED ARAB EMIRATES ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM ANTIBACTERIAL DRUGS MARKET SIZE, BY ROUTES OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM ANTIBACTERIAL DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 148. UNITED KINGDOM ANTIBACTERIAL DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 149. ANTIBACTERIAL DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 150. ANTIBACTERIAL DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!